Challenges for the treatment of diabetes mellitus

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 5, Issue 3, 2011, Pages 203-209

  Papazafiropoulou, Athanasia K ^a   Kardara, Marina S ^a   Pappas, Stavros I ^a  

^a 3rd Department of Internal Medicine   (Greece)

Author keywords

Bile acid synthesis; Free fatty acids; Glucokinase activators; SGLT2 inhibitors

Indexed keywords

ANTIDIABETIC AGENT; BILE ACID; DAPAGLIFLOZIN; FATTY ACID; G PROTEIN COUPLED RECEPTOR 40; GLUCOKINASE ACTIVATOR; GPR119 PROTEIN; GPR41 PROTEIN; GPR43 PROTEIN; MEMBRANE PROTEIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PROTEIN INHIBITOR; REMOGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

BILE ACID METABOLISM; BILE ACID SYNTHESIS; CONSTIPATION; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DRUG MECHANISM; GENITAL TRACT INFECTION; HUMAN; MEDICAL LITERATURE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARATHYROID HORMONE BLOOD LEVEL; PATENT; PRERENAL AZOTEMIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UREMIA; URINARY TRACT INFECTION;

ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; GLUCOKINASE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PYRAZOLES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 80052864530     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221411797265953     Document Type: Review

References (81)

1. International Diabetes Federation (IDF). Diabetes Atlas. Available at: http://www.diabetesatlas.org.[Accessed on: March 25, 2009]
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29(Suppl 1): S43-S48
3. Fan T, Koro CE, Fedder DO, Bowlin SJ. Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002. Diabetes Care 2006; 29: 1924-5
4. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27:17-20
5. Isaji M: Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007; 8: 285-92
6. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004; 447: 510-18
7. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na /glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93:397-404
8. Santer R, Calado, J. Familial renal glucosuria and SGLT2: From a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5:133-41
9. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, et al. Lack of early proximal tubular glucose reabsorption in transgenic Sglt2 null mice. J Am Soc Nephrol 2011;22(1):104-12
10. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a selective SGLT-2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9
11. Jabbour SA, Goldstein, BJ. Sodium-glucose cotransporter 2 inhibitors: Blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-84
12. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991; 87: 561-70
13. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care 2009; 32: 650-7
14. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-30
15. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-6
16. Komoroski B, Brenner E, Li L. Dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, inhibits glucose resorption and reduces fasting glucose in patients with type 2 diabetes mellitus. Diabetologia 2007; 50(Suppl 1): S315
17. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A pilot study of dapagliflozin in patients with type 2 diabetes on high doses of insulin plus insulin sensitizers: applicability of a novel insulin-ndependent treatment. Diabetes Care 2009; 32: 1656-62
18. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-76
19. th Scientific Session of the American Diabetes Association, New Orleans, USA (2009)
20. Kapur AR, Hussey E, Dobbins RL, Tao W, Hompesch M, Nunez, DJ. First human dose escalation study with remogliflozin etabonate(RE) in healthy subjects and in subjects with type 2 diabetes mellitus. 69th Scientific Session of the American Diabetes Association, New Orleans, USA (2009)
21. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-9
22. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI; Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group.Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23: 1737-41
23. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
24. Agius L, Peak M, Newgard CB, Gomez-Foix AM, Guinovart JJ. Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis. J Biol Chem 1996; 273: 30479-86
25. Vionnet N, Stoffel M, Takeda J, Yasuda K, Bell GI, Zouali H, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulindependent diabetes mellitus (Letter). Nature 1992; 356: 721-2
26. Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, et al. The second activating glucokinase mutation (A456V): Implications for glucose homeostasis and diabetes therapy. Diabetes 2002; 51: 1240-6
27. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 1999; 274: 305-15
28. Hariharan N, Farrelly D, Hagan D, Hillyer D, Arbeeny C, Sabrah T, et al. Expression of human hepatic glucokinase in transgenic mice liver results in decreased glucose levels and reduced body weight. Diabetes 1997; 46:11-6
29. Desai UJ, Slosberg ED, Boettcher BR, Caplan SL, Fanelli B, Stephan Z, et al. Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression. Diabetes 2001; 50: 2287-95
30. Iynedjian PB. Mammalian glucokinase and its gene. Biochem J 1993; 293: 1-13
31. Van Schaftingen E, Detheux M, Veiga-da-Cunha M. Short-term control of glucokinase activity: role of a regulatory protein. FASEB J 1994; 8: 414-19
32. Veiga-da-Cunha M, Van Schaftingen E. Identification of fructose 6-phosphate-and fructose 1-phosphate-binding residues in the regulatory protein of glucokinase. J Biol Chem 2002; 277: 8466-73
33. Agius L, Peak M. Intracellular binding of glucokinase in hepatocytes and translocation by glucose, fructose and insulin. Biochem J 1993; 296:785-96
34. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, et al. Allosteric activators of glucokinase: Potential role in diabetes therapy. Science 2003; 301: 370-3
35. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009; 8: 399-416
36. Pal M. Recent advances in glucokinase activators for treatment of type 2 diabetes. Drug Discovery Today 2009; 14: 784-92
37. Grimsby J, Matschinsky FM, Grippo JF. Discovery and actions of glucokinase activators. In Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes. Vol. 16. Edited by Matschinsky FM, Magnuson MA. Basel: Karger; 2004:360-78
38. Bonadonna RC, Kapitza C, Heinse T, Avogaro A, Boldrin M, Grimsby J, et al. Glucokinase activator RO4389620 improves beta cell function and plasma glucose indexes in patients with type 2 diabetes. Diabetologia 2008; 51(Suppl 1): S371
39. Zhai S, Mulligan ME, Grimsby J, Arbet-Engels C, Boldrin M, Balena R, et al. Phase I assessment of a novel glucose activator RO4389620 in healthy male volunteers. Diabetologia 2008; 51 (Suppl 1): S372
40. Array BioPhama: Glucokinase Activator ARRY-403: Phase 1 Single Ascending Dose Top-Line Results. August 10, 2009
41. Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 1998; 47: 1613-8
42. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-38
43. Newgard CB, McGarry JD. Metabolic coupling factors in pancreatic beta-cell signal transduction. Annu Rev Biochem 1995; 64: 689-719
44. Prentki M, Tornheim K, Corkey BE. Signal transduction mechanisms in nutrient-induced insulin secretion. Diabetologia 1997; 40 (Suppl. 2): 32-41
45. Prentki M, Joly E, El-Assad W, Roduit, R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: A role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002; 51 (Suppl. 3): 405-13
46. Haber EP, Procopio J, Carvalho CR, Carpinelli AR, Newsholme P, Curi R. New insights into fatty acid modulation of pancreatic betacell function. Int Rev Cytol 2006; 248: 1-41
47. Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun 2005; 335: 97-104
48. Katsuma S, Hatae N, Yano T, Ruike Y, Kimura M, Hirasawa A, et al. Free fatty acids inhibit serum deprivation-induced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1. J Biol Chem 2005; 280: 19507-15
49. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005; 1: 245-58
50. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006; 2: 16-23
51. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003; 422: 173-6
52. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 1999; 111: 241-8
53. Bollheimer LC, Landauer HC, Troll S, Schweimer J, Wrede CE, Schölmerich J, et al. Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism 2004; 53: 1443-8
54. Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahrén B, Salehi A. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 2007; 354: 240-5
55. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, Littleton TR, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278: 11312-9
56. Sakamoto Y, Inoue H, Kawakami S, Miyawaki K, Miyamoto T, Mizuta K, et al. Expression and distribution of GPR119 in the pancreatic islets of mice and rats: Predominant localization in pancreatic polypeptidesecreting PP-cells. Biochem Biophys Res Commun 2006; 351: 474-80
57. Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005; 326: 744-51
58. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006; 3: 167-75
59. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72: 137-74
60. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, doubleblind, crossover trial. Ann Intern Med 1994; 121: 416-22
61. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168: 1975-83
62. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008; 31: 1479-84
63. Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, FutamiSuda S, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007; 74: 338-43
64. Andersen E, Karlaganis G, Sjovall J. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur J Clin Invest 1988; 18: 166-72
65. Uchida K, Makino S, Akiyoshi T. Altered bile acid metabolism in nonobese, spontaneously diabetic (NOD) mice. Diabetes 1985; 34: 79-83
66. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004; 53:890-8
67. th Annual Meeting and Scientific Sessions of the American Diabetes Association. New Orleans USA (2009)
68. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 2010; 298: G419-24
69. Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: A pilot study. Metab Syndr Relat Disord 2010; 8: 179-88
70. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-940
71. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-9
72. Nguyen A, Bouscarel, B. Bile acids and signal transduction: Role in glucose homeostasis. Cell Signal 2008; 20: 2180-97
73. Maruyama T, Tanaka K, Suzuki J, Miyoshi H, Harada N, Nakamura T, et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrino 2006; 191: 197-205
74. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386-90
75. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10:167-177
76. Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun 2007; 362: 793-8
77. Berthel, S.J., Chen, L., Corbett, W.L., Feng, L., Haynes, N.E., Kester, R.F., So, S.-S., Tilley, J. Azaindole glukcokinase activators. US20110144105 (2011) & WO2011073117 (2011)
78. Nomura, S., Kawanishi, E., Ueta, K. Glucopyranoside compound. US7943788 (2011)
79. Berthel, S.J., Kester, R.F., Murphy, D.E., Prins, T.J., Ruebsam, F.S., Sarabu, R., Tran, C. V., Vourloumis, D. Pyrazole glucokinase activators. US7935699 (2011)
80. Haynes, N.E., Scott, N.R., Tilley, J.W. Pyridone glukcokinase activators. US20110021570 (2011) & WO2011009845 (2011)
81. Lau, J., Murray, A., Vedso, P., Kristiansen, M., Jeppesen, L. Ureido-thiazole glucokinase activators. US7884210 (2011)